LLY vs NKE: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and NIKE, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Eli Lilly and Company · Healthcare
$939.47
+71.1% upside to fair value
High Conviction
Grade A
VS
NIKE, Inc. · Consumer Cyclical
$42.62
+45.5% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
LLY has more upside to fair value
(+71.1%).
LLY trades at a lower forward P/E
(27.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
NKE |
| Current Price |
$939.47 |
$42.62 |
| Fair Value Estimate |
$1,607.00 |
$62.00 |
| Upside to Fair Value |
+71.1%
|
+45.5%
|
| Market Cap |
$887.6B |
$63.0B |
| Forward P/E |
27.4x
|
27.9x
|
| EV / EBITDA |
35.8x
|
20.7x
|
| Price / Sales |
14.8x
|
1.4x
|
| Price / FCF |
107.6x
|
19.4x
|
| Revenue Growth YoY |
+44.7%
|
-9.8%
|
| Gross Margin |
83.8%
|
42.7%
|
| Operating Margin |
45.6%
|
8.0%
|
| Return on Equity |
77.8%
|
24.4%
|
| Dividend Yield |
0.56% |
3.8% |
| FCF Yield |
0.93%
|
5.2%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Eli Lilly remains the dominant GLP-1 franchise holder with Mounjaro and Zepbound generating $36.5B combined in 2025 on 45% total revenue growth to $65.2B. The company guided $80-83B for 2026, well above prior Street consensus, and launched Foundayo (oral GLP-1, FDA approved April 2026) with $1.5B pre-built inventory. At $939 the stock trades at 14.8x P/S, right at its 5-year median, and 27.4x for…
Nike is the world's largest athletic footwear and apparel company with $46.3B in FY2025 revenue, operating across 190+ countries with the Nike, Jordan, and Converse brands. The stock trades near its 9-year low at $42.62 after an 11% single-day crash following a Q3 FY2026 earnings report that showed 35% net income decline and weak Q4 guidance calling for a further 2-4% revenue decline. FY2025 reve…
Accumulation Zones
| Metric |
LLY |
NKE |
| Zone Low |
$1,205.00 |
$44.00 |
| Zone High |
$1,366.00 |
$50.00 |
| In Buy Zone? |
Yes
|
Yes
|